Neeltje Steeghs

Neeltje Steeghs is chair of the Dutch Pharmacology Oncology Group and chair of the Dutch GIST consortium Her scientific interest lies mainly in the development of new medicines, including conducting clinical phase I and early phase II studies and the knowledge of pharmacokinetics and pharmacodynamics in these studies Her area of interest also lies in the design aspect of early clinical trials.

In addition to her clinical activities, she was a Clinical Assessor for the Medicines Evaluation Board of the European Medicines Agency (2009-2011), chair of the Dutch Sarcoma Study Group, board member for the Pediatric Oncology Research Foundation (2010-2013), junior researcher for the EORTC Soft Tissue and Bone Sarcoma Group (2013-2016), chair of the multidisciplinary expert board for the Center for Personalized Cancer Treatment (2012-2015) and vice chair of the Medical Ethics Committee of the Netherlands Cancer Institute She is also a board member of the Assessment of Oncological Drugs Committee (cieBOM), the Dutch Working Group on Interaction of Oncological Agents and the Translational Research Board of the Netherlands Cancer Institute. She is editor for Gastrointestinal Stromal Tumor (GIST), Frontiers in Oncology; Pharmacology of Anti-Cancer Drugs and guest editor for the journal Cancers. She is currently head of the Clinical Research Department at the Netherlands Cancer Institute in Amsterdam and also an advisor to various pharmaceutical companies regarding clinical trials.

Neeltje Steeghs has been the principal investigator of both investigator-initiated research and industry-sponsored studies for many years, and is considered one of the foremost authorities in the field of research into safe and effective dosage of anticancer drugs. She is the author of more than 150 scientific articles and has given numerous lectures at international conventions.

Specialism and interests

• Early drug development and clinical trials
• Targeted therapies
• Personalized dosing
• Research design and dosing strategies
• Researcher-initiated research into pharmacological concepts
• GIST, sarcomas

Publications

View Neeltje Steeghs' publications .

Relevant committees/networks/other relevant experience

• Board member of the Early Phase Clinical Trials group of Cancer Core Europe
• Member of the Methodology for the Development of Innovative Cancer Therapies (MDICT) group. In 2022: Identifying the optimal dose - practical issues and recommendations for the conduct and design of phase I studies.
• Chairman of the Dutch Pharmacology Oncology Group
• Chairman of the Dutch GIST consortium
• Vice-Chair of the Medical Ethics Committee of the Netherlands Cancer Institute
• Board member of the committee Assessment of Oncological Drugs (cieBOM)
• Board member of the Dutch Working Group on the Interaction of Oncological Drugs
• Board member of the Translational Research Board of the Netherlands Cancer Institute
• Editor for Gastrointestinal Stromal Tumor (GIST), Frontiers in Oncology; Pharmacology of Anti-Cancer Drugs and guest editor for the journal Cancers.
• Clinical assessor for the Medicines Evaluation Board of the European Medicines Agency (2009-2011)
• Former chairman of the Dutch Sarcoma Study Group
• Former board member of the Paediatric Oncology Research Foundation (2010-2013)
• Former young researcher for the EORTC Soft Tissue and Bone Sarcoma Group (2013-2016)
• Former Chair of the Multidisciplinary Board of Experts for the Center for Personalized Cancer Treatment (2012-2015)